Skip to main content
SpringerLink
Log in

Drug holidays in osteoporosis treatment: mind the gaps!

  • Letter to the Editor
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nayak S, Greenspan SL (2019) A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk. Osteoporos Int 30:705–720. https://doi.org/10.1007/s00198-018-4791-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Trémollieres FA, Goulis DG (2017) Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 101:23–30

    Article  CAS  Google Scholar 

  3. Black D, Schwartz A, Ensrud K et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296:2927–2938

    Article  CAS  Google Scholar 

  4. Bone H, Hosking D, Devogelaer J et al (2004) Alendronate phase III osteoporosis treatment study group (2004) ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199

    Article  CAS  Google Scholar 

  5. Black D, Reid I, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 27:243–254

    Article  CAS  Google Scholar 

  6. Black D, Reid I, Cauley J et al (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 30:934–944

    Article  CAS  Google Scholar 

  7. Schilcher J, Koeppen V, Aspenberg P, Michaelsson K (2014) Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med 371:974–976

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynaecology, Medical School, “Papageorgiou” General Hospital, Aristotle University of Thessaloniki, 56403, Nea Efkarpia, Thessaloniki, Greece

    P. Anagnostis & D.G. Goulis

  2. Center of Orthopaedic and Regenerative Medicine Research (CORE), Center for Interdisciplinary Research and Innovation (CIRI), Aristotle University of Thessaloniki, Thessaloniki, Greece

    P. Anagnostis, E. Kenanidis, M. Potoupnis, E. Tsiridis & D.G. Goulis

  3. Academic Orthopaedic Unit, General Hospital “Papageorgiou”, Aristotle University Medical School, Thessaloniki, Greece

    P. Anagnostis, E. Kenanidis, M. Potoupnis & E. Tsiridis

  4. Second Department of Obstetrics and Gynaecology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

    I. Lambrinoudaki

Authors
  1. P. Anagnostis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Lambrinoudaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Kenanidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Potoupnis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Tsiridis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D.G. Goulis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Anagnostis.

Ethics declarations

Conflict of interest

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anagnostis, P., Lambrinoudaki, I., Kenanidis, E. et al. Drug holidays in osteoporosis treatment: mind the gaps!. Osteoporos Int 30, 2523–2524 (2019). https://doi.org/10.1007/s00198-019-05027-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-019-05027-1

Search

Navigation